Safety, tolerability and pharmacokinetic profile of Macozinone (PBTZ169) formulated as native crystal powder: multiple ascendingdoses, phase-Ib trial in healthy volunteers
Chtioui H., Prod'Hom S., Desfontaine V., André P., Moulfi F., Bardinet C., Abo-Loha C., Tessieras J., Rothuizen L.E., Diezi L. et al., 2022. dans 15th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT) - June 2022 Athens. European Journal of Clinical Pharmacology, 2022, 78: 1-163.
ici le détail